The demand for artificial pancreas devices has increased lately as the cases related to pancreatic ailments and failures have grown substantially. The market is set to attain revenues valued at USD 341.08 million while forging ahead at a CAGR of 21.10% in the upcoming forecast period between 2017 and 2023. The escalating number of cases being diagnosed with diabetes is the key factor in promoting the development of the market. The rising inflow of investment in the market is expected to improve the product quality, thus increasing the sales of the market. As patients these days are more or less aware of the treatment options, they are also increasingly involved in the selection of their treatment options in certain cases. This factor is anticipated to reflect positively in the expansion of the artificial pancreas devices market in the upcoming forecast period.
Companies Covered
Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp
Segmental Analysis
The segmentation of the artificial pancreas device market has been carried out to better gauge the market.
By Type
- CTR (Control to Range) Systems
- CTT (Control To Target) Systems
By End User
- Hospitals
- Medical Centers
By Region
- North America
- South America
- Europe
- Asia-Pacific
- Middle East
- Africa
Request Customization
Get a Sample
Get a Sample
Request Customization